Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. more
Time Frame | CVKD | Sector | S&P500 |
---|---|---|---|
1-Week Return | 2.65% | 0.49% | -0.42% |
1-Month Return | 28.72% | -3.1% | -2.2% |
3-Month Return | 44.36% | -8.59% | 2.38% |
6-Month Return | 133.26% | -4.57% | 5.1% |
1-Year Return | 64.34% | -0.94% | 23.79% |
3-Year Return | -73.67% | 2.88% | 26.66% |
Dec '22 | Dec '23 | |||||
---|---|---|---|---|---|---|
Total Revenue | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Cost of Revenue | 1.27K | 1.98K | [{"date":"2022-12-31","value":63.94,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |||
Gross Profit | (1.27K) | (1.98K) | [{"date":"2022-12-31","value":-126600,"profit":false},{"date":"2023-12-31","value":-198000,"profit":false}] | |||
Gross Margin | - | (Infinity%) | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":null,"profit":false}] | |||
Operating Expenses | 2.70M | 7.63M | [{"date":"2022-12-31","value":35.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |||
Operating Income | (2.70M) | (7.63M) | [{"date":"2022-12-31","value":-270163000,"profit":false},{"date":"2023-12-31","value":-763284300,"profit":false}] | |||
Total Non-Operating Income/Expense | - | (492.25K) | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-49225200,"profit":false}] | |||
Pre-Tax Income | (6.71M) | (8.36M) | [{"date":"2022-12-31","value":-671432900,"profit":false},{"date":"2023-12-31","value":-835708600,"profit":false}] | |||
Income Taxes | 4.00 | (165.91K) | [{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-4147875,"profit":false}] | |||
Income After Taxes | - | (8.19M) | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-819117100,"profit":false}] | |||
Income From Continuous Operations | - | (8.36M) | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-835708600,"profit":false}] | |||
Income From Discontinued Operations | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Net Income | (6.71M) | (8.36M) | [{"date":"2022-12-31","value":-671432900,"profit":false},{"date":"2023-12-31","value":-835708600,"profit":false}] | |||
EPS (Diluted) | (0.91) | (8.03) | [{"date":"2022-12-31","value":-91,"profit":false},{"date":"2023-12-31","value":-803.29,"profit":false}] | |||
These ratios help you determine the liquidity of the company. Higher is better.
CVKD | |
---|---|
Cash Ratio | 3.44 |
Current Ratio | 3.69 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CVKD | |
---|---|
ROA (LTM) | -70.99% |
ROE (LTM) | -125.15% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CVKD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.27 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.73 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CVKD | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 8.65 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.21 |
Cadrenal Therapeutics, Inc. Common Stock (CVKD) share price today is $16.27
Yes, Indians can buy shares of Cadrenal Therapeutics, Inc. Common Stock (CVKD) on Vested. To buy Cadrenal Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CVKD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cadrenal Therapeutics, Inc. Common Stock (CVKD) via the Vested app. You can start investing in Cadrenal Therapeutics, Inc. Common Stock (CVKD) with a minimum investment of $1.
You can invest in shares of Cadrenal Therapeutics, Inc. Common Stock (CVKD) via Vested in three simple steps:
The 52-week high price of Cadrenal Therapeutics, Inc. Common Stock (CVKD) is $32.55. The 52-week low price of Cadrenal Therapeutics, Inc. Common Stock (CVKD) is $5.4.
The price-to-earnings (P/E) ratio of Cadrenal Therapeutics, Inc. Common Stock (CVKD) is
The price-to-book (P/B) ratio of Cadrenal Therapeutics, Inc. Common Stock (CVKD) is 8.65
The dividend yield of Cadrenal Therapeutics, Inc. Common Stock (CVKD) is 0.00%
The market capitalization of Cadrenal Therapeutics, Inc. Common Stock (CVKD) is $29.00M
The stock symbol (or ticker) of Cadrenal Therapeutics, Inc. Common Stock is CVKD